Evommune Inc (EVMN)

$12.96 +0.14 (1.09%)
Market Cap 466.79M
Revenue (ttm) 13.00M
Net Income (ttm) -68.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -529.77%
Debt to Equity Ratio 0.00
Volume 1,344,500
Avg Vol 727,424
Day's Range N/A - N/A
Shares Out 36.02M
Stochastic %K 3%
Beta N/A
Analysts Strong Sell
Price Target $40.12

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (925) 247-4481
Address:
1891 Page Mill Road, Palo Alto, United States
Lanuchbox
Lanuchbox Jul. 4 at 6:09 PM
$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT
0 · Reply
Robby83
Robby83 Jul. 2 at 4:24 PM
$EVMN well back down to my entry... lots of selling pressure breaking my chart setup
0 · Reply
Timefortendies77
Timefortendies77 Jul. 1 at 9:00 PM
$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.
0 · Reply
Tradr1205
Tradr1205 Jul. 1 at 2:52 PM
$EVMN Just loaded up!!
0 · Reply
HenrikTheBandit
HenrikTheBandit Jul. 1 at 2:23 PM
$EVMN averaged out, put it all in $CELH
0 · Reply
changf
changf Jul. 1 at 11:57 AM
$EVMN I just buy it at $13.5。
0 · Reply
MarketPulsee
MarketPulsee Jun. 30 at 10:18 PM
$EVMN Morgan Stanley lowered Evommune’s price target to $26 from $55, while maintaining an Overweight rating. HC Wainwright downgraded the stock to Neutral from Buy following a clinical trial failure. Analysts noted that the investment thesis is now weakened, as the stock is no longer supported by two previously credible mid-stage mechanisms, significantly reducing visibility on the pipeline.
0 · Reply
nUme22
nUme22 Jun. 30 at 6:31 PM
$EVMN 8-10 is the buyzone.
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 30 at 6:29 PM
$EVMN should be $18-$20 minimum here. very nice i like
0 · Reply
Mburrryyy
Mburrryyy Jun. 30 at 4:36 PM
$EVMN Slowly building my position here. I believe.
0 · Reply
Latest News on EVMN
Septerna price target lowered to $45 from $52 at Guggenheim

2026-07-01T10:50:37.000Z - 3 days ago

Septerna price target lowered to $45 from $52 at Guggenheim

SEPN

Evommune price target lowered to $26 from $55 at Morgan Stanley

2026-06-30T11:00:29.000Z - 4 days ago

Evommune price target lowered to $26 from $55 at Morgan Stanley

Evommune downgraded to Neutral from Buy at H.C. Wainwright

2026-06-30T10:05:57.000Z - 4 days ago

Evommune downgraded to Neutral from Buy at H.C. Wainwright

Evommune price target lowered to $28 from $53 at Clear Street

2026-06-29T20:20:55.000Z - 4 days ago

Evommune price target lowered to $28 from $53 at Clear Street

Evommune downgraded to Market Perform from Outperform at William Blair

2026-06-29T13:40:41.000Z - 5 days ago

Evommune downgraded to Market Perform from Outperform at William Blair

Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint

2026-06-29T12:35:45.000Z - 5 days ago

Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Jun 29, 2026, 8:30 AM EDT - 5 days ago

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

2026-06-22T21:55:09.000Z - 11 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

ABBV APGE

Evommune Transcript: AGM 2026

Jun 2, 2026, 11:30 AM EDT - 4 weeks ago

Evommune Transcript: AGM 2026

Evommune price target raised to $55 from $54 at Morgan Stanley

2026-05-11T15:52:55.000Z - 7 weeks ago

Evommune price target raised to $55 from $54 at Morgan Stanley

Evommune reports Q1 EPS (64c), consensus (71c)

2026-05-07T22:50:50.000Z - 2 months ago

Evommune reports Q1 EPS (64c), consensus (71c)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026, 4:05 PM EDT - 2 months ago

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Evommune Quarterly report: Q1 2026

Evommune Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Evommune Earnings release: Q1 2026

Evommune Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 2 months ago

Evommune Slides: Corporate presentation

Evommune initiated with a Buy at Stifel

2026-04-30T20:39:05.000Z - 2 months ago

Evommune initiated with a Buy at Stifel

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Evommune Proxy statement: Proxy filing

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Evommune Proxy statement: Proxy filing

Evommune Registration statement: Registration filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Evommune Registration statement: Registration filing

Evommune Transcript: Status update

Apr 13, 2026, 2:00 PM EDT - 2 months ago

Evommune Transcript: Status update

Evommune assumed with an Outperform at Oppenheimer

2026-04-07T14:18:01.000Z - 3 months ago

Evommune assumed with an Outperform at Oppenheimer

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Apr 6, 2026, 9:00 AM EDT - 3 months ago

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune price target lowered to $50 from $65 at H.C. Wainwright

2026-03-18T10:12:14.000Z - 3 months ago

Evommune price target lowered to $50 from $65 at H.C. Wainwright

Evommune initiated with a Buy at Clear Street

2026-03-17T20:25:28.000Z - 3 months ago

Evommune initiated with a Buy at Clear Street

Evommune initiated with an Outperform at RBC Capital

2026-03-10T10:11:40.000Z - 4 months ago

Evommune initiated with an Outperform at RBC Capital

Evommune reports Q4 EPS ($1.43), consensus (84c)

2026-03-05T21:06:11.000Z - 4 months ago

Evommune reports Q4 EPS ($1.43), consensus (84c)

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Mar 5, 2026, 4:01 PM EST - 4 months ago

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

Evommune Earnings release: Q4 2025

Evommune Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

Evommune Annual report: Q4 2025

Evommune Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 4 months ago

Evommune Slides: Corporate presentation

Evommune Announces $125 Million Private Placement

Feb 12, 2026, 8:30 PM EST - 5 months ago

Evommune Announces $125 Million Private Placement

Evommune Transcript: Study result

Feb 10, 2026, 8:30 AM EST - 5 months ago

Evommune Transcript: Study result

Evommune Press release: Study result

Feb 10, 2026, 8:30 AM EST - 5 months ago

Evommune Press release: Study result

Evommune Slides: Study result

Feb 10, 2026, 8:30 AM EST - 5 months ago

Evommune Slides: Study result

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Feb 10, 2026, 7:30 AM EST - 5 months ago

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 6 months ago

Evommune Slides: Corporate presentation

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Dec 11, 2025, 4:05 PM EST - 7 months ago

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune Quarterly report: Q3 2025

Dec 11, 2025, 4:00 PM EST - 7 months ago

Evommune Quarterly report: Q3 2025

Evommune Earnings release: Q3 2025

Dec 11, 2025, 4:00 PM EST - 7 months ago

Evommune Earnings release: Q3 2025

Evommune Slides: Corporate Presentation

Dec 11, 2025, 4:00 PM EST - 7 months ago

Evommune Slides: Corporate Presentation

Evommune Announces Pricing of its Initial Public Offering

Nov 5, 2025, 7:45 PM EST - 8 months ago

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering

Oct 30, 2025, 6:30 AM EDT - 8 months ago

Evommune Announces Commencement of Initial Public Offering

Evommune Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 9 months ago

Evommune Registration statement: Registration Filing

Evommune files for IPO to advance immune drug work

Oct 10, 2025, 8:31 AM EDT - 9 months ago

Evommune files for IPO to advance immune drug work

Evommune IPO Registration Document (S-1)

Oct 9, 2025, 2:18 PM EDT - 9 months ago

Evommune IPO Registration Document (S-1)

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

Oct 9, 2025, 10:32 AM EDT - 9 months ago

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

Lanuchbox
Lanuchbox Jul. 4 at 6:09 PM
$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT
0 · Reply
Robby83
Robby83 Jul. 2 at 4:24 PM
$EVMN well back down to my entry... lots of selling pressure breaking my chart setup
0 · Reply
Timefortendies77
Timefortendies77 Jul. 1 at 9:00 PM
$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.
0 · Reply
Tradr1205
Tradr1205 Jul. 1 at 2:52 PM
$EVMN Just loaded up!!
0 · Reply
HenrikTheBandit
HenrikTheBandit Jul. 1 at 2:23 PM
$EVMN averaged out, put it all in $CELH
0 · Reply
changf
changf Jul. 1 at 11:57 AM
$EVMN I just buy it at $13.5。
0 · Reply
MarketPulsee
MarketPulsee Jun. 30 at 10:18 PM
$EVMN Morgan Stanley lowered Evommune’s price target to $26 from $55, while maintaining an Overweight rating. HC Wainwright downgraded the stock to Neutral from Buy following a clinical trial failure. Analysts noted that the investment thesis is now weakened, as the stock is no longer supported by two previously credible mid-stage mechanisms, significantly reducing visibility on the pipeline.
0 · Reply
nUme22
nUme22 Jun. 30 at 6:31 PM
$EVMN 8-10 is the buyzone.
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 30 at 6:29 PM
$EVMN should be $18-$20 minimum here. very nice i like
0 · Reply
Mburrryyy
Mburrryyy Jun. 30 at 4:36 PM
$EVMN Slowly building my position here. I believe.
0 · Reply
bigtex66
bigtex66 Jun. 30 at 3:33 PM
$EVMN end of quarter adding pressure. Nobody wants to show it on their books. Could bounce some tomorrow beginning of new quarter.
0 · Reply
ValueBioTracker
ValueBioTracker Jun. 30 at 8:57 AM
$EVMN Should be back around $18-20
0 · Reply
Timefortendies77
Timefortendies77 Jun. 30 at 12:30 AM
$EVMN Well I guess $CLDX now can be the clear mast cell winner with nothing coming anywhere near close behind them. All hail Celldex let's do this!
0 · Reply
Trump_is_King_Cope
Trump_is_King_Cope Jun. 29 at 10:15 PM
$EVMN
1 · Reply
TurboGains69
TurboGains69 Jun. 29 at 7:59 PM
$EVMN adding heavily
0 · Reply
Major_High_Finance_Stud
Major_High_Finance_Stud Jun. 29 at 6:37 PM
$EVMN Have to agree with bowlcut boy Shkreli here. Burden is now gone and future pipeline is discounted.
0 · Reply
Don_Frye
Don_Frye Jun. 29 at 6:25 PM
$EVMN 36 million shares outstanding 98% tutes. ''only'' 6 million traded for now . looks like most firms are just holding
0 · Reply
prismmarketview
prismmarketview Jun. 29 at 4:39 PM
PRISM Mid-Day Movers: Aerospace & Defense and AI Datacenter & Infrastructure are Today’s Leaders. Astrotech Corporation (NASDAQ: $ASTC ) is putting in a big upside move today, with the stock up about 42% in the latest session as traders pile into this thinly traded micro‑cap. EdgeMode, Inc. (OTC: $EDGM) is ripping higher again today, with the stock up about 37% to 0.0026 from a prior close of 0.0019. Other Notable Movers: Biotricity ( $BTCY) up 36% FuelCell Energy ( $FCEL) up 24% Evommune, Inc. ( $EVMN ) down -36% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-ai-datacenter-infrastructure-are-todays-leaders/
0 · Reply
wisdom_trade
wisdom_trade Jun. 29 at 3:20 PM
$EVMN go to $0
1 · Reply
ValueBioTracker
ValueBioTracker Jun. 29 at 2:40 PM
$EVMN Also, data readout for AD in 26Q3, a much more important indication
0 · Reply
TurboGains69
TurboGains69 Jun. 29 at 2:31 PM
$EVMN shkreli says buy so I buy
1 · Reply
ValueBioTracker
ValueBioTracker Jun. 29 at 2:28 PM
$EVMN 30% drop is way too much. It's just for one indication. Should rebound
0 · Reply